Calcium-phosphate-adjuvanted allergens: total and specific IgE levels before and after immunotherapy with house dust and Dermatophagoides pteronyssinus extracts.
Results of total and specific IgE levels before and after immunotherapy carried out with calcium-phosphate-adjuvanted house dust and mite allergens for 36 patients are reported here. Total and specific IgE levels were evaluated by radioimmunological methods based on the IgE/anti-IgE interaction. Total IgE levels were not significantly different before and after immunotherapy; most of the specific IgE levels remained on the same order. IgE levels after immunotherapy varied only slightly in most patients and were not correlated with therapeutic results. Advantages of calcium phosphate compared to aluminium compounds are reported.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D000818:Animals; D000918:Antibody Specificity; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000276:immunology*; D003888:Desensitization, Immunologic; D004391:Dust / Q000009:adverse effects*; D006798:Housing; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000096:biosynthesis*; D008925:Mites / Q000276:immunology*; D011852:Radioallergosorbent Test; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000485:Allergens; D002130:Calcium Phosphates; D004391:Dust; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D007073:Immunoglobulin E; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous